Teva Pharmaceuticals
TEVA
650 hedge funds and large institutions have $20.2B invested in Teva Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 94 funds opening new positions, 235 increasing their positions, 196 reducing their positions, and 64 closing their positions.
69% more call options, than puts
Call options by funds: $703M | Put options by funds: $416M
47% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 64
20% more repeat investments, than reductions
Existing positions increased: 235 | Existing positions reduced: 196
3% more funds holding
Funds holding: 629 → 650 (+21)
2.06% less ownership
Funds ownership: 59.91% → 57.85% (-2.1%)
6% less capital invested
Capital invested by funds: $21.4B → $20.2B (-$1.29B)
32% less funds holding in top 10
Funds holding in top 10: 38 → 26 (-12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM Investment Management
Laguna Beach,
California
|
+$863M |
| 2 |
BlackRock
New York
|
+$220M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$208M |
| 4 |
JP Morgan Chase
New York
|
+$179M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$132M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
-$324M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$196M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$124M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$116M |
| 5 |
DFO
Duquesne Family Office
New York
|
-$113M |
TEVA Hedge Fund Activity: Q1 2026 in Review
650 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2026, worth a combined $20.2B — down 6% from $21.4B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new TEVA positions and 64 closed out — a net gain of 30 holders — while 235 added to existing stakes and 196 trimmed.
The largest buyer was WCM Investment Management, adding an estimated $863M. The largest seller was Glenview Capital Management, cutting an estimated $324M.
- 650 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2026, up from 629 in Q4 2025.
- Funds reported $20.2B of Teva Pharmaceuticals stock for Q1 2026, down 6% quarter-over-quarter.
- 94 funds opened new Teva Pharmaceuticals positions in Q1 2026 and 64 closed out, a net change of +30 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2026 was WCM Investment Management, an estimated $863M added.
- The largest Teva Pharmaceuticals seller in Q1 2026 was Glenview Capital Management, an estimated $324M sold.
Based on aggregated 13F filings for Q1 2026.